November 7, 2023 10:35 AM EST
News Briefing

Sage’s PPD drug to cost $15K; Ab­cam share­hold­ers vote 'yes' on Dana­her deal

Jaimy Lee

Deputy Editor

Plus, news about Sen­ti Bio­sciences, Ce­lest Ther­a­peu­tics and Au­ra Bio­sciences:

Sage’s post­par­tum de­pres­sion drug to cost $15K for 14 days: The com­pa­ny

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times